Primary androgen deprivation ineffective for most early prostate cancer

In a study of men with early stage prostate cancer, those who received androgen deprivation as their primary treatment instead of surgery or radiation did not live any longer than those who received no treatment.

Molecular test prompts changes in prostate cancer treatment plans

The PROCEDE 500 study demonstrated that 65% of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.

Bone turnover markers predict prostate cancer outcomes

Bone turnover markers predict prostate cancer outcomes

Biomarkers for the formation and resorption of bone predict outcomes for men with castration-resistant prostate cancer (CRPC).

Younger men benefit most from surgery for localized prostate cancer

Younger men benefit most from surgery for localized prostate cancer

A new study found substantial long-term reduction in mortality for men with localized prostate cancer who undergo a radical prostatectomy.

PADT does not lower mortality for localized prostate cancer

PADT does not lower mortality for localized prostate cancer

For localized prostate cancer, primary androgen-deprivation therapy does not prolong survival for the majority of men who have not received treatment with curative intent.

Patients desire specific prostate cancer information

Patients desire specific prostate cancer information

Although patients with prostate cancer endorse multiple sources of information, they report greatest satisfaction with information from the treating physician about patient outcomes.

Prostatectomy lowers early prostate cancer mortality

Prostatectomy lowers early prostate cancer mortality

Risk of long-term mortality for those that undergo surgical treatment is lower, compared with men who choose watchful waiting.

Robot-assisted prostatectomy yields improved surgical margins

Robot-assisted prostatectomy yields improved surgical margins

Robot-assisted radical prostatectomy (RARP) is associated with improved surgical margin status compared with open radical prostatectomy (ORP) for intermediate- and high-risk disease.

Key cellular pathway in prostate cancer identified

The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.

Genetic mutation in prostate cancer linked to later aggressive cancer

Genetic mutation in prostate cancer linked to later aggressive cancer

A new study examined how a genetic mutation in untreated patients is linked to aggressive prostate cancer later in life.

3D mapping biopsy finds 3x more prostate cancer than ultrasound biopsy

Three-dimensional biopsies find more prostate cancers, particularly in the anterior regions, than those guided by ultrasound, according to a new clinical study.

Key gene inhibits prostate cancer metastasis

Key gene inhibits prostate cancer metastasis

New evidence lends support to the hypothesis that the SSeCKS/AKAP12 gene is a key inhibitor of prostate cancer metastasis.

Multiple biopsies increase infection risk for prostate cancer patients

Multiple biopsies increase infection risk for prostate cancer patients

Men with prostate cancer on active surveillance should be informed of the risk of complications linked to repeated biopsies.

Prognostic test modifies treatment decisions for prostate cancer patient

Prognostic test modifies treatment decisions for prostate cancer patient

Results from PROCEDE 500, a clinical utility study with the Prolaris test, demonstrated the significant clinical value of Prolaris to physicians who are treating men with prostate cancer.

Why exercise improves prostate cancer outcomes

Why exercise improves prostate cancer outcomes

Men who walked at a fast pace prior to a prostate cancer diagnosis had more regularly shaped blood vessels in their prostate tumors compared with men who walked slowly, providing a potential explanation for why exercise is linked to improved outcomes.

ASCO: Enzalutamide effective for metastatic prostate cancer

ASCO: Enzalutamide effective for metastatic prostate cancer

Two beneficial treatment approaches are available for metastatic and locally advanced prostate cancer, according to two studies presented in advance of ASCO's annual Genitourinary Cancers Symposium.

Too soon to say if soy is a promising ­adjuvant for radiotherapy

Too soon to say if soy is a promising ­adjuvant for radiotherapy

Soy and soy isoflavones are alleviating skin and lung toxicities from thoracic radiotherapy in preclinical study models; however, researchers stress the need for further studies.

Additional prostate cancer criteria may help ID surveillance candidates

Additional prostate cancer criteria may help ID surveillance candidates

Additional predictors guide selection of patients with prostate cancer for active surveillance programs.

AACR: Exercise improves vessel shape in prostate cancer

AACR: Exercise improves vessel shape in prostate cancer

Brisk walking before prostate cancer diagnosis has been associated with more regularly-shaped blood vessels.

Nomogram determines individualized estimates of screen-detected prostate cancer overdiagnosis

Nomogram determines individualized estimates of screen-detected prostate cancer overdiagnosis

Using a nomogram that incorporates age, Gleason score, and prostate-specific antigen level at diagnosis, individual risks that a screen-detected prostate cancer has been overdiagnosed can be estimated.

AACR: Higher melatonin levels tied to lower prostate cancer risk

AACR: Higher melatonin levels tied to lower prostate cancer risk

After adjusting for potential confounders, men with high levels of 6-sulfatoxymelatonin demonstrated a significantly lower prostate cancer risk.

Pain drugs used during prostate gland removal linked to cancer outcome

The methods used to anesthetize patients with prostate cancer and control pain due to surgical resection of the prostate glands for adenocarcinoma may affect patients' long-term cancer outcomes, a study has found.

Early BPA exposure may increase later prostate cancer risk

Early BPA exposure may increase later prostate cancer risk

In vivo BPA exposure has been tied to increased incidence of prostate intraepithelial neoplasia and adenocarcinoma.

Prostate cancer biomarker may predict patient outcomes

A cell-surface protein called CD151 may serve as a biomarker that accurately predicts which patients with prostate cancer are likely to experience metastasis or recurrence.

Coordinated approach is needed for castrate-resistant prostate cancer

With a deluge of promising new treatments for advanced prostate cancer, a new model of care is needed that emphasizes collaboration between urology and medical oncology clinicians.

Neuraxial plus general anesthesia may improve prostate CA outcomes

Neuraxial plus general anesthesia may improve prostate CA outcomes

Supplementing general anesthesia (GA) with neuraxial anesthesia during prostate cancer surgery is associated with improved oncological outcomes compared with GA alone.

Integrated care optimal for castration-resistant prostate cancer

Framework for optimizing CRPC treatment should involve joint management by both a urologist and a medical oncologist.

Protein in prostate biopsies signals increased risk of cancer

The presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. This discovery is likely to help physicians to decide how closely to monitor men who are potentially at risk for prostate cancer, which is one of the most confusing and controversial dilemmas in health care.

Statins lower risk of dying from prostate cancer

Men with prostate cancer who take the cholesterol-lowering drugs known as statins are significantly less likely to die from their cancer than men who do not take such medication, according to a new study.

Oral drug may improve survival for patients with prostate cancer

An investigational prostate cancer treatment slows the disease's progression and may increase survival, especially among men whose cancer has spread to the bones. This study adds long-term survival and safety data for the drug tasquinimod, a new candidate for treating advanced and recurrent prostate cancer.

Fish oil diet proves beneficial for prostate cancer

Fish oil diet proves beneficial for prostate cancer

Fish oil consumption affects levels of pro-inflammatory molecules, omega fatty acids, measure of cancer growth.

New biomarkers for aggressive prostate cancer

Vesicles released from aggressive prostate cancer cells with highly migratory features, known as large oncosomes, may be a new source of biomarkers for aggressive prostate cancer.

Low-fat fish oil diet changes cancer tissue in men with prostate cancer

Men with prostate cancer who ate a low-fat diet and took fish oil supplements had lower levels of proinflammatory substances in their blood than men who ate a typical Western diet.

IMRT allows treatment of pelvic nodes individualized by including sentinel nodes

Treatment of pelvic nodes individualized by inclusion of sentinel nodes can be easily integrated into an intensity-modulated radiation therapy (IMRT)-based treatment strategy, according to a new study.

Tumor genetics customize treatments for deadly prostate cancer

A new study is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer.

Qigong fights fatigue in prostate cancer survivors

Qigong fights fatigue in prostate cancer survivors

The flowing movements and meditative exercises of the mind-body activity known as Qigong may help survivors of prostate cancer to combat fatigue, according to a newly published trial study.

Weight at time of diagnosis tied to prostate cancer mortality

Weight at time of diagnosis tied to prostate cancer mortality

Men with prostate cancer who are overweight or obese at diagnosis are more likely to die from the disease than men who are of healthy weight, according to a newly published study.

Postdiagnostic statin use lowers prostate cancer mortality

Postdiagnostic statin use lowers prostate cancer mortality

For men with prostate cancer, postdiagnostic statin use is associated with a decreased risk of prostate cancer and all-cause mortality, with stronger effects seen for those who used statins before diagnosis, according to a study.

Interactive online program helps patients with prostate cancer make treatment decisions

When the pros and cons of prostate cancer treatment are spelled out using an online interactive program, more patients choose active surveillance over therapy, according to research.

History of prostate cancer increases melanoma risk

History of prostate cancer increases melanoma risk

The risk of melanoma was significantly increased with personal history of PCa, whereas the risk of non-melanoma skin cancer was marginally increased with PCa.

BMI linked to mortality for prostate cancer

BMI linked to mortality for prostate cancer

or men with prostate cancer, body mass index (BMI) at diagnosis is associated with mortality, according to a study.

Circulating tumor cell levels may have predictive value in prostate cancer

Changes in circulating tumor cell levels may predict treatment outcomes in castration-resistant prostate cancer more accurately than changes in prostate-specific antigen levels, according to a study.

AACR: Biomarkers ID'd that mark breast cancer progression

AACR: Biomarkers ID'd that mark breast cancer progression

Biomarkers have been identified that vary with breast cancer progression, and short telomere length associated with increased risk of aggressive prostate cancer.

Symptoms from prostate biopsy can increase male anxiety

Symptoms from prostate biopsy can increase male anxiety

Potential psychological harm associated with biopsy even in absence of cancer diagnosis

Metastatic Cancer (Fact Sheet)

This fact sheet reviews common sites of cancer metastasis, methods of spread, treatment, and additional details.

ASA: Serum fatty acids can serve as cancer biomarkers

ASA: Serum fatty acids can serve as cancer biomarkers

Serum free fatty acids and metabolites are one- to six-fold higher in patients with lung or prostate cancer.

Men undergoing hormone therapy don't benefit from women's hot flash remedies

Hot flashes occur in approximately 80% of men who are undergoing hormone manipulation as treatment for prostate cancer. However, neither soy protein nor a common antidepressant provides relief from hot flashes for men.

Long-term HT does not improve overall survival in intermediate-risk prostate cancer

Men with intermediate-risk prostate cancer who received long-term hormonal therapy (HT) after radiation had no additional benefits compared to short-term hormonal therapy.

Abiraterone delayed pain in men with metastatic prostate cancer

Men with mCRPC who had not undergone previous chemotherapy reported delayed pain progression and prolonged health-related quality of life with abiraterone acetate plus prednisone, compared with prednisone alone.

Prostate cancer screening costs in 2009 reach 447 M

Prostate cancer screening costs in 2009 reach $447 M

Biopsy-related procedures accounted for much of the prostate cancer screening costs.

Nomograms: Predictive tool for prostate cancer management

Nomograms: Predictive tool for prostate cancer management

These tools can help clinicians determine which treatments are ideal and explain to patients what their best options are and why.

ASTRO/AUA co-issue guideline on radiation for prostate cancer

The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) have set forth several recommendations on radiation therapy after prostatectomy.

Three-gene test can identify which prostate cancers require treatment

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow growing, according to new research.

Implications of VLR prostate cancer assessed

Implications of VLR prostate cancer assessed

Gleason score upgrade or non-organ confined cancer is double for men with low risk prostate cancer.

Lifestyle intervention iassociated with increased telomere length

Lifestyle intervention iassociated with increased telomere length

Lifestyle intervention tied to increases in telomere length in men with low-risk prostate cancer.

FDA approves new device for enlarged prostate

FDA approves new device for enlarged prostate

UroLift system, a permanent implant, has been approved by the U.S. Food and Drug Administration to treat low or blocked urine flow in men aged 50 and older.

High-risk prostate tumors can differ

Gleason 8 tumors have a substantially better prognosis after radical surgery than Gleason 9 and 10 tumors.

Three-gene panel shows whether low-risk prostate cancer will stay that way

Researchers have identified a gene signature that is expected to help predict which low-risk prostate tumors will become lethal.

PSADT may give incorrect prostate cancer prognosis

Relying on PSA doubling time from just one year of active surveillance can result in as many as one in five prostate cancer patients being advised to undergo curative treatment that may be unnecessary.

Genetic mutation discovered in castration-resistant prostate cancer

New research has found that the androgen-synthesizing enzyme 3βHSD1 has a mutation that enables a tumor to make its own supply of androgens, which are the hormones that fuel the growth of prostate cancer.

Prostate cancer grade usually does not progress over time

The proportion of men with advanced-stage prostate tumors at diagnosis has dropped dramatically since the widespread implementation of PSA screening, but the proportion of men with aggressive cancers at diagnosis has not changed substantially.

Drug reduces prostate cancer risk but has no impact on survival

After 18 years of follow-up, the drug finasteride was shown to reduce the risk for prostate cancer by approximately one third, but did not significantly affect overall survival in men or survival after prostate cancer diagnosis.

Coffee intake associated with prostate cancer recurrence

Coffee intake associated with prostate cancer recurrence

Higher coffee consumption is linked to lower risk of prostate cancer recurrence/progression.

Key mechanism in aggressive prostate cancer targeted

A team of researchers has identified a key mechanism behind aggressive prostate cancer.

Percentage of cancers linked to viruses potentially overestimated

A large-scale analysis of the association between DNA viruses and human malignancies suggests that many of the most common cancers are not associated with DNA viruses

Finasteride offers no long-term prostate cancer survival benefit

Finasteride offers no long-term prostate cancer survival benefit

Finasteride is linked to reduction in the risk of prostate cancer, but no decrease in mortality over 18 years, per a recent study.

Swedish study demonstrates sharing data reduces unnecessary prostate cancer scans

The rate of inappropriate cancer scans for low-risk prostate cancer patients in Sweden plummeted in the decade following a joint campaign to curtail such tests. The campaign was run by the Swedish County Councils and the National Prostate Cancer Register (NPCR) of Sweden

MRI-guided cryoablation an option for prostate cancer

MRI-guided cryoablation an option for prostate cancer

Promising initial results for 10 patients with recurrent prostate cancer after radiation

Radium-223 prolongs life in advanced prostate cancer

Radium-223 dichloride (Xofigo) significantly improved overall survival and caused few adverse events in men with castration-resistant prostate cancer (CRPC) that had metastasized to bone, researchers reported.

Cumulative metformin connected to post-prostate cancer mortality

Cumulative metformin connected to post-prostate cancer mortality

Among elderly men with diabetes, increased cumulative duration of metformin following a prostate cancer (PC) diagnosis correlates with decreased all-cause and PC-specific mortality.

Androgen deprivation for prostate cancer can harm kidneys

Androgen deprivation therapy (ADT) was significantly associated with an increased risk for acute kidney injury in a large study of men with nonmetastatic prostate cancer.

Walnuts protect against prostate cancer

New research indicates that eating a modest amount of walnuts can protect against prostate cancer.

Decision aid assists prostate cancer screening choices

Decision aid assists prostate cancer screening choices

An aid helps men with their decision making about prostate cancer screening, but the print and web-based aids do not affect screening rates.

Prostate cancer recurrence not reduced by soy supplement

Among men who had undergone radical prostatectomy, daily consumption of a soy protein supplement did not reduce or delay development of biochemical recurrence of prostate cancer

Prostate screening not always a shared decision

Most men in the United States report little shared decision making between them and their physicians in terms of choosing or declining to undergo prostate-specific antigen screening.

Nerves may play key role in triggering prostate cancer and its spread

Nerves play a critical role in both the development and spread of prostate tumors.

Lifestyle factors impact prostate cancer severity

Lifestyle factors impact prostate cancer severity

Adherence to lifestyle recommendations can reduce risk of aggressive prostate cancer.

Radiation oncologists underuse quality-of-life tools

Radiation oncologists underuse quality-of-life tools

Only 23 and 27 percent of radiation oncologists and urologists use quality-of-life and life-expectancy instruments, respectively.

Androgen deprivation therapy for prostate cancer associated with risk for acute kidney injury

In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk for acute kidney injury.

Radium-223 extends survival for metastatic prostate cancer

Radium-223 extends survival for metastatic prostate cancer

A Phase 3 randomized trial was halted when interim analysis showed radium-223 was superior to placebo used in combination with best standard of care in men with castration-resistant prostate cancer.

Prostate cancer treatment associated with kidney harm

Prostate cancer treatment associated with kidney harm

Androgen deprivation is associated with acute kidney injury in non-metastatic prostate cancer.

Active surveillance of prostate cancer may be risky in African Americans

African American men with very-low-risk prostate cancer, and who meet criteria for active surveillance, but undergo immediate surgery are much more likely than men of other races to actually have aggressive disease.

Genetic variants that predict aggressive prostate cancers identified

A method has been developed to identify aggressive prostate cancers that require immediate therapy.

Soy supplement doesn't reduce prostate cancer recurrence

Soy supplement doesn't reduce prostate cancer recurrence

No reduction in biochemical recurrence within two years of radical prostatectomy, despite daily soy protein ingestion.

Active surveillance a reasonable approach for patients with low-risk prostate cancer

Many men with low-risk, localized prostate cancers can safely choose active surveillance or "watchful waiting" and have better QoL while reducing health care costs, according to a new study.

Cancer clinical guidelines fall short of IOM standards

The vast majority of oncology clinical practice guidelines (CPGs) fail to meet the Institute of Medicine (IOM) standards for trustworthy guidelines, according to a recent evaluation published by Journal of Clinical Oncology.

Biodegradable implant may lessen radiation side effects in prostate cancer

A device designed to increase the space between the prostate and the rectum in prostate cancer patients undergoing radiation therapy has the potential to significantly reduce rectal injury.

High-tech therapies used more to treat low-risk prostate cancer

High-tech therapies used more to treat low-risk prostate cancer

Use of advanced treatment technologies is up in men at low risk of diagnosed with prostate cancer.

Aspirin's colon cancer prevention limited

Aspirin's colon cancer prevention limited

Regular aspirin only lowers risk of BRAF-wild-type colorectal cancer, according to a study by the Journal of the American Medical Association.

Recurrent prostate cancer can be effectively imaged with PET and MR

Simultaneously combining positron emission tomography (PET) and magnetic resonance (MR) has a higher capacity to map recurrent prostate cancer than the already high standard of integrated PET and computed tomography (CT), according to research.

'Index patients' aid mCRPC guideline

'Index patients' aid mCRPC guideline

The AUA developed its new clinical guideline on castration-resistant prostate cancer by creating six index patients to represent the most common clinical scenarios encountered when managing the disease.

New drug class may stop advanced prostate cancer

Researchers at The University of Texas Southwestern Medical Center in Dallas, Texas, have developed a class of drugs known as peptidomimetics, which disrupt androgen receptor activity in a unique way.

African-Americans show poorer outcomes for low-risk prostate cancer

African-Americans show poorer outcomes for low-risk prostate cancer

Worse outcomes are seen for African-American men with low-risk prostate cancer who undergo prostatectomy, according to a study published online in the Journal of Clinical Oncology.

Men with comparable prostate cancer show similar outcomes despite prostatectomy timing

Men with comparable prostate cancer show similar outcomes despite prostatectomy timing

Finding in men with similar prostate conditions undergoing watchful waiting versus immediate surgery proved to be similar.

Converting urology practice to IPCC affects cancer treatment

Converting urology practice to IPCC affects cancer treatment

Integrated prostate cancer centers have greater use of intensity modulated radiation therapy and lower use of androgen deprivation therapy, when compared to urology practices.

Urine test could detect prostate cancer

Chemists at the University of California-Irvine (UC Irvine) have developed a technology to identify clinically usable markers for prostate cancer in urine.

Similar genetic origins for some aggressive prostate cancers

Next generation genomic analysis has determined that some of the more aggressive prostate cancers have similar genetic origins, according to a recent publication

Replacing carbohydrates with vegetable fats lowers prostate CA mortality

Replacing carbohydrates with vegetable fats lowers prostate CA mortality

Replacement of 10 percent of carbohydrates with vegetable fat cuts lethal prostate cancer risk and also all-cause mortality.

A roundup of FDA news from May 2013

FDA-related news items of relevance from the month of May, 2013.

Depression hikes risk of death after cancer

Survivors of cancer with depressive symptoms were twice as likely to die prematurely as survivors who were not depressed, a prospective study demonstrated.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs